Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 23,100 shares, a decline of 12.5% from the March 15th total of 26,400 shares. Currently, 0.3% of the company’s shares are sold short. Based on an average trading volume of 39,600 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently bought a new position in Alterity Therapeutics stock. Virtu Financial LLC bought a new position in Alterity Therapeutics Limited (NASDAQ:ATHE) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,799 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 0.27% of Alterity Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 2.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and set a $4.00 price objective on shares of Alterity Therapeutics in a research note on Thursday, March 7th.

Alterity Therapeutics Trading Down 11.0 %

NASDAQ:ATHE traded down $0.27 during mid-day trading on Tuesday, hitting $2.18. 338,914 shares of the company’s stock were exchanged, compared to its average volume of 77,954. Alterity Therapeutics has a one year low of $1.55 and a one year high of $5.41. The business has a fifty day moving average price of $1.92 and a 200 day moving average price of $2.20.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.